CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
| Bid date, 2022-04-26 | |
| Auction date | 2022-04-26 |
| Settlement date | 2022-04-27 |
| Maturity Date | 2022-05-04 |
| Nominal amount | 592 billion SEK |
| Interest rate, % | 0.00 |
| Bid times | 09.30-10.00 (CET/CEST) on the Bid date |
| Confirmation of bids to e-mail | rbcert@riksbank.se |
| The lowest accepted bid volume | 1 million SEK |
| The highest accepted bid volume | 592 billion SEK |
| Allocation Time | 10.15 (CET/CEST) on the Bid date |
| Projected minimum liquidity surplus during the term | 1183 billion SEK |
| Expected excess liquidity at full allotment | 591 billion SEK |
Stockholm, 2022-04-26
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Equinor ASA: Nøkkelinformasjon ved kontantutbytte for første kvartal 202425.4.2024 06:46:29 CEST | Pressemelding
Nøkkelinformasjon ved kontantutbytte for Equinor (OSE: EQNR, NYSE: EQNR) for første kvartal 2024. Ordinært utbyttebeløp: 0,35 Ekstraordinært utbyttebeløp: 0,35 Annonsert valuta: USD Siste dag inklusive: 15. august 2024 Ex-dato Oslo Børs: 16. august 2024 Ex-dato New York Stock Exchange: 19. august 2024 Record date (eierregisterdato): 19. august 2024 Betalingsdato: 28. august 2024 Vedtaksdato: 24. april 2024 Øvrig informasjon: Kontantutbytte i NOK per aksje vil bli kommunisert 23. august 2024. Denne informasjonen offentliggjøres i henhold til kravene i Løpende forpliktelser og er informasjonspliktig i henhold til verdipapirhandelloven §5-12.
Equinor ASA: Key information relating to cash dividend for first quarter 202425.4.2024 06:46:29 CEST | Press release
Key information relating to the cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for first quarter 2024. Ordinary cash dividend amount: 0.35 Extraordinary cash dividend amount: 0.35 Announced currency: USD Last day including rights: 15 August 2024 Ex-date Oslo Børs: 16 August 2024 Ex-date New York Stock Exchange: 19 August 2024 Record date: 19 August 2024 Payment date: 28 August 2024 Date of approval: 24 April 2024 Other information: The cash dividend per share in NOK will be communicated 23 August 2024. This information is published in accordance with the requirements of the Continuing Obligations and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.
Equinors resultater for første kvartal 202425.4.2024 06:45:00 CEST | Pressemelding
Equinor (OSE: EQNR, NYSE: EQNR) leverte et justert driftsresultat* på 7,53 milliarder USD, og 2,57 milliarder USD etter skatt i første kvartal 2024. Det rapporterte driftsresultatet var 7,63 milliarder USD, og resultatet for perioden var 2,67 milliarder USD. Justert resultat* var 2,84 milliarder USD, noe som ga et justert resultat per aksje* på 0,96 USD. Finansielle resultater og drift God drift og høy produksjonSolide finansielle resultater og kontantstrømSterke resultater fra tradingvirksomheten Strategisk framgang Kraft fra land til Sleipner- og Gudrun-feltene på norsk sokkelNy kraftsalgsavtale tildelt Empire Wind 1Forbedret gassportefølje på land i USA gjennom transaksjon Konkurransedyktig kapitaldistribusjon Ordinært kontantutbytte på 0,35 USD per aksjeFortsatt ekstraordinært kontantutbytte på 0,35 USD per aksje. Andre transje i tilbakekjøpsprogrammet på inntil 1,6 milliarder USDForventet total kapitaldistribusjon i 2024 på 14 milliarder USD. Anders Opedal, konsernsjef i Equinor A
Equinor first quarter 2024 results25.4.2024 06:45:00 CEST | Press release
Equinor (OSE: EQNR, NYSE: EQNR) delivered adjusted operating income* of USD 7.53 billion and USD 2.57 billion after tax in the first quarter of 2024. Equinor reported net operating income of USD 7.63 billion and net income at USD 2.67 billion. Adjusted net income* was USD 2.84 billion, leading to adjusted earnings per share* of USD 0.96. Financial and operational performance Strong operational performance and productionSolid financial results and cash flowHigh results from marketing and trading Strategic progress Power-from-shore to the Sleipner and Gudrun fields on NCSEmpire Wind 1 awarded new offtake agreementAnnounced high-grading of US onshore gas position Capital distribution First quarter ordinary cash dividend of USD 0.35 per shareContinued extraordinary cash dividend of USD 0.35 per share and second tranche of share buy-back of up to USD 1.6 billionExpected total capital distribution for 2024 of USD 14 billion Anders Opedal, President and CEO of Equinor ASA: “Equinor delivered
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab25.4.2024 04:11:25 CEST | Press release
SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug Office, Department of Health, the Government of the Hong Kong Special Administrative Region (“DO”) has recently accepted the New Drug Application (“NDA”) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (“NPC”), and as a single agent for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. The NDA is supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational multi-center Phase 3 clinical study (NCT03581786) that examined toripalimab in combina